GlassScriptPhysician profile
Laura Ann Davis
NPI 1780691063
$4,842.12
in general payments reported to CMS, 2019-2025
24 companies · $988 in 2025
The $988 reported for 2025 was more than what 89% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.94 · 2022: $647 · 2023: $906 · 2024: $2,245 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127 · Consulting Fee: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.99 |
| Consulting Fee | $1,012.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,529.16 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $923.43 | 2021-2025 | Myrisk, Mychoice Cdx |
| Astrazeneca Pharmaceuticals LP | $355.34 | 2023-2025 | Lynparza, Imfinzi, Enhertu |
| Immunogen, INC. | $288.60 | 2023-2024 | Elahere, Elahere |
| Merck Sharp & Dohme LLC | $243.88 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $239.12 | 2023-2025 | Jemperli, Zejula |
| Medtronic, INC. | $170.36 | 2022 | |
| Seagen INC. | $158.60 | 2022-2023 | Tivdak, Padcev |
| Janssen Biotech, INC. | $138.20 | 2022-2024 | Talvey, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $137.66 | 2022-2025 | |
| Eisai INC. | $112.37 | 2022-2024 | |
| Tempus Ai, INC | $100.86 | 2024 | |
| Pfizer INC. | $74.35 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $74.17 | 2024-2025 | |
| Astellas Pharma US INC | $50.06 | 2025 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $45.49 | 2024-2025 | Enhertu, Vanflyta |
| Incyte Corporation | $44.04 | 2024-2025 | Jakafi, Monjuvi |
| Edwards Lifesciences Corporation | $39.04 | 2024 | Hemosphere |
| Lilly USA, LLC | $24.07 | 2024 | Verzenio, Retevmo, Jaypirca |
| Genentech USA, INC. | $19.62 | 2025 | Itovebi |
| Blueprint Medicines Corporation | $19.15 | 2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $19.09 | 2025 | Libtayo |
| Clovis Oncology, INC. | $18.44 | 2022 | |
| Sobi, INC | $17.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.